Statements (274)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:accessories |
with multiple countries
|
| gptkbp:acquired |
gptkb:Novartis_vaccines_business
|
| gptkbp:acquisition |
gptkb:Affinivax
gptkb:Galvani_Bioelectronics gptkb:Tetra_Logic_Pharmaceuticals gptkb:Zynerba_Pharmaceuticals gptkb:Glaxo_Wellcome gptkb:Zy_Co_V-D gptkb:Alder_Bio_Pharmaceuticals gptkb:Clover_Health gptkb:Smith_Kline_Beecham |
| gptkbp:adjuvant_used |
AS03
|
| gptkbp:awards |
Top Employer Global 2021
Sustainability Leader 2020 Best Workplaces 2020 |
| gptkbp:ceo |
gptkb:Emma_Walmsley
|
| gptkbp:clinical_trial |
gptkb:gene_therapy
gptkb:diabetes gptkb:Shingrix gptkb:Compliance_Management gptkb:Duloxetine gptkb:Benlysta gptkb:Nucala gptkb:vaccine gptkb:Cell mental health quality assurance data analytics neurology oncology patient engagement rare diseases Phase 3 market access dermatology cardiovascular diseases biologics infectious diseases diverse populations immunology global presence pain management children's health digital health pharmacovigilance therapeutic areas women's health health economics respiratory diseases vaccinology ophthalmology Phase 1, Phase 2, Phase 3 real-world evidence urology gastroenterology regulatory affairs over 100 ongoing clinical trials management medical affairs scientific communications for vaccine development clinical supply chain |
| gptkbp:collaborates_with |
various global health organizations
|
| gptkbp:collaboration |
with governments worldwide
|
| gptkbp:community_engagement |
disaster relief efforts
health education programs global health initiatives |
| gptkbp:community_health |
aims to reduce COVID-19 cases
|
| gptkbp:developed_by |
gptkb:Shingrix
gptkb:Pandemrix gptkb:Bexsero gptkb:vaccine |
| gptkbp:dividend_yield |
$2.00 per share (2022)
|
| gptkbp:employees |
99,000 (2020)
approximately 99,000 99,000 (2022) |
| gptkbp:focus |
gptkb:pharmaceuticals
Pharmaceuticals research and development vaccines consumer healthcare |
| gptkbp:focuses_on |
pharmaceuticals, vaccines, consumer healthcare
|
| gptkbp:founded |
gptkb:2000
|
| gptkbp:founder |
merger of Glaxo Wellcome and Smith Kline Beecham
|
| gptkbp:has |
over 100,000 employees
|
| gptkbp:has_a_pipeline_of |
over 40 vaccines
|
| gptkbp:has_partnerships_with |
gptkb:Bill_&_Melinda_Gates_Foundation
gptkb:CEPI gptkb:GAVI gptkb:WHO |
| gptkbp:has_received |
numerous awards for innovation
|
| gptkbp:has_research_center |
gptkb:Stevenage,_UK
gptkb:RTP,_North_Carolina gptkb:Rixensart,_Belgium gptkb:Ware,_UK gptkb:Zhangjiang,_China in the UK in Belgium in the USA |
| gptkbp:headquarters |
gptkb:Brentford,_England
Brentford, London, England |
| gptkbp:hepatitis_vaccine |
gptkb:Engerix-B
|
| gptkbp:hpv_vaccine |
gptkb:Cervarix
|
| https://www.w3.org/2000/01/rdf-schema#label |
GSK
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:influenza_vaccine |
gptkb:Flu_Laval
|
| gptkbp:invention |
biologics patents
pharmaceutical patents vaccine patents |
| gptkbp:investment |
research and development
|
| gptkbp:is_a_member_of |
gptkb:EFPIA
gptkb:ICMRA gptkb:Ph_RMA IMI |
| gptkbp:is_committed_to |
community engagement
public health initiatives sustainability initiatives global health equity vaccine accessibility innovation in vaccines |
| gptkbp:is_displayed_in |
gptkb:London_Stock_Exchange
|
| gptkbp:is_involved_in |
clinical trials for vaccines
|
| gptkbp:is_recognized_for |
sustainability efforts
community support programs vaccine development expertise global health contributions commitment to R& D |
| gptkbp:is_vulnerable_to |
gptkb:GSK-Sanofi_COVID-19_vaccine
gptkb:vaccine non-profit organizations regulatory compliance new technologies global supply chain disease prevention public health campaigns intramuscular injection clinical trial results cold chain logistics in multiple countries post-marketing surveillance emergency response efforts low-income countries with NGOs inactivated vaccines subunit vaccines clinical immunology live attenuated vaccines with international health organizations monitored through surveys optimized for efficiency immunology studies accelerated due to pandemic against severe disease protein subunit vaccine standard refrigeration with biotech firms Flu vaccine affordable pricing strategies liquid suspension adverse event monitoring ongoing for new variants provided to healthcare professionals m RNA vaccines healthcare professional training Shingles vaccine collaboration with Sanofi clinical trials for new diseases assessed in clinical trials 70% in clinical trials addressed during rollout conducted by independent boards for long-term effects prioritized for outreach. secured from governments to COVAX initiative |
| gptkbp:malaria_vaccine |
gptkb:Mosquirix
|
| gptkbp:manufacturing_capacity |
increased for COVID-19 vaccine
|
| gptkbp:measles_vaccine |
gptkb:M-M-R_II
|
| gptkbp:operates |
in over 100 countries
|
| gptkbp:operates_in |
over 100 countries
|
| gptkbp:partnership |
gptkb:Bill_&_Melinda_Gates_Foundation
gptkb:Astra_Zeneca gptkb:Sanofi gptkb:Bristol-Myers_Squibb gptkb:World_Health_Organization gptkb:Pfizer gptkb:Merck_&_Co. gptkb:Regeneron gptkb:Novartis Sanofi for COVID-19 vaccine with WHO |
| gptkbp:philanthropy |
GSK IMPACT Awards
partnership with Save the Children GSK's Global Health Programs partnership with the Global Fund partnership with the World Health Organization |
| gptkbp:pneumococcal_vaccine |
gptkb:Synflorix
|
| gptkbp:produces |
vaccines
|
| gptkbp:products |
antibiotics
vaccines oral health products |
| gptkbp:received_approval_for |
gptkb:Boostrix
gptkb:Flu_Laval gptkb:Menveo |
| gptkbp:regulatory_compliance |
gptkb:European_Medicines_Agency
gptkb:U._S._Food_and_Drug_Administration |
| gptkbp:research |
oncology
biopharmaceuticals infectious diseases immunology respiratory diseases consumer healthcare |
| gptkbp:research_and_development |
$6 billion (2022)
|
| gptkbp:research_focus |
COVID-19 variants
|
| gptkbp:revenue |
£34.1 billion (2020)
$43 billion (2022) |
| gptkbp:safety_features |
monitored post-vaccination
|
| gptkbp:stock_exchange |
gptkb:London_Stock_Exchange
|
| gptkbp:stock_symbol |
gptkb:GSK
|
| gptkbp:subsidiaries |
gptkb:Vii_V_Healthcare
HIV research |
| gptkbp:subsidiary |
gptkb:Haleon
gptkb:Vii_V_Healthcare gptkb:Stiefel_Laboratories HIV research |
| gptkbp:sustainability |
environmental initiatives
community health programs diversity and inclusion initiatives |
| gptkbp:sustainability_efforts |
diversity and inclusion
carbon neutrality by 2030 access to medicines |
| gptkbp:sustainability_initiatives |
environmental impact reduction
|
| gptkbp:tetanus_vaccine |
gptkb:Tdap
|
| gptkbp:traded_on |
gptkb:LSE
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:vaccine_approval_process |
expedited due to emergency use
|
| gptkbp:vaccine_approvals |
regulatory agencies
|
| gptkbp:vaccine_booster |
under investigation
|
| gptkbp:vaccine_clinical_data |
published in peer-reviewed journals
|
| gptkbp:vaccine_clinical_endpoints |
focused on hospitalization and death
|
| gptkbp:vaccine_clinical_trial_diversity |
ensured for inclusivity
|
| gptkbp:vaccine_clinical_trial_results |
reported to the public
|
| gptkbp:vaccine_collaboration |
with academic institutions
|
| gptkbp:vaccine_collaborations |
academic institutions
international health organizations |
| gptkbp:vaccine_data |
shared with regulatory agencies
|
| gptkbp:vaccine_development_strategy |
focused on rapid response
|
| gptkbp:vaccine_distribution_logistics |
coordinated with partners
|
| gptkbp:vaccine_distribution_network |
established globally
|
| gptkbp:vaccine_effectiveness_studies |
ongoing post-approval
|
| gptkbp:vaccine_funding |
government grants
|
| gptkbp:vaccine_impact_assessment |
conducted post-deployment
|
| gptkbp:vaccine_market |
global health initiatives
|
| gptkbp:vaccine_outreach |
community engagement programs
to underserved communities |
| gptkbp:vaccine_patents |
intellectual property rights
|
| gptkbp:vaccine_pipeline |
future vaccine candidates
|
| gptkbp:vaccine_production |
scaled up rapidly
|
| gptkbp:vaccine_production_technology |
innovative and scalable
|
| gptkbp:vaccine_public_health_strategy |
aligned with global health goals
|
| gptkbp:vaccine_research_outcomes |
shared with scientific community
|
| gptkbp:vaccine_safety_data |
continuously updated
|
| gptkbp:vaccine_target |
SARS-Co V-2 virus
|
| gptkbp:vaccine_technology |
adjuvants
nanoparticle vaccines vector vaccines based on recombinant DNA |
| gptkbp:vaccine_technology_transfer |
to manufacturing partners
|
| gptkbp:vaccine_trials |
in children and adolescents
in various demographics |
| gptkbp:bfsParent |
gptkb:biotechnology
gptkb:W3_C |
| gptkbp:bfsLayer |
3
|